Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $34 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) and maintained a $34 price target.
March 14, 2024 | 2:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Catalyst Pharmaceuticals and maintained a $34 price target.
The reiteration of an Overweight rating and maintenance of a $34 price target by a reputable analyst suggests a positive outlook for Catalyst Pharmaceuticals, likely leading to increased investor confidence and potential upward movement in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100